Cancer Stemness: P53 at the Wheel

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jan 28

PMID 33505918

Citations 28

Authors

Dishari Ghatak

Damayanti Das Ghosh

Susanta Roychoudhury

Affiliations

Soon will be listed here.

Abstract

The tumor suppressor p53 maintains an equilibrium between self-renewal and differentiation to sustain a limited repertoire of stem cells for proper development and maintenance of tissue homeostasis. Inactivation of p53 disrupts this balance and promotes pluripotency and somatic cell reprogramming. A few reports in recent years have indicated that prevalent oncogenic (GOF) mutations further boosts the stemness properties of cancer cells. In this review, we discuss the role of wild type p53 in regulating pluripotency of normal stem cells and various mechanisms that control the balance between self-renewal and differentiation in embryonic and adult stem cells. We also highlight how inactivating and GOF mutations in p53 stimulate stemness in cancer cells. Further, we have explored the various mechanisms of mutant p53-driven cancer stemness, particularly emphasizing on the non-coding RNA mediated epigenetic regulation. We have also analyzed the association of cancer stemness with other crucial properties of mutant p53 such as epithelial to mesenchymal transition phenotypes and chemoresistance to understand how activation of one affects the other. Given the critical role of cancer stem-like cells in tumor maintenance, cancer progression, and therapy resistance of mutant p53 tumors, targeting them might improve therapeutic efficacy in human cancers with mutations.

Citing Articles

A Truncated Mutation of TP53 Promotes Chemoresistance in Tongue Squamous Cell Carcinoma.

Du X, Zheng J, Lu X, Zhang Y Int J Mol Sci. 2025; 26(5).

PMID: 40076972 PMC: 11900931. DOI: 10.3390/ijms26052353.

Genetically Engineered Brain Organoids Recapitulate Spatial and Developmental States of Glioblastoma Progression.

Ishahak M, Han R, Annamalai D, Woodiwiss T, McCornack C, Cleary R Adv Sci (Weinh). 2025; 12(10):e2410110.

PMID: 39836549 PMC: 11905097. DOI: 10.1002/advs.202410110.

Decoding the molecular symphony: interactions between the mA and p53 signaling pathways in cancer.

Shoemaker R, Huang M, Wu Y, Huang C, Lee D NAR Cancer. 2024; 6(3):zcae037.

PMID: 39329012 PMC: 11426327. DOI: 10.1093/narcan/zcae037.

CircCFL1 Promotes TNBC Stemness and Immunoescape via Deacetylation-Mediated c-Myc Deubiquitylation to Facilitate Mutant TP53 Transcription.

Wang Z, Li Y, Yang J, Sun Y, He Y, Wang Y Adv Sci (Weinh). 2024; 11(34):e2404628.

PMID: 38981022 PMC: 11425638. DOI: 10.1002/advs.202404628.

Influence of Aldehyde Dehydrogenase Inhibition on Stemness of Endometrial Cancer Stem Cells.

Serambeque B, Mestre C, Correia-Barros G, Teixo R, Marto C, Goncalves A Cancers (Basel). 2024; 16(11).

PMID: 38893151 PMC: 11171353. DOI: 10.3390/cancers16112031.

References

Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F . MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2011; 19(6):1038-48. PMC: 3354056. DOI: 10.1038/cdd.2011.190. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I . Cancer stem cells and angiogenesis. Int J Dev Biol. 2011; 55(4-5):477-82. DOI: 10.1387/ijdb.103225yz. View

Blandino G, Di Agostino S . New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30. PMC: 5815234. DOI: 10.1186/s13046-018-0705-7. View

Lee K, Li M, Michalowski A, Zhang X, Liao H, Chen L . A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proc Natl Acad Sci U S A. 2009; 107(1):69-74. PMC: 2806696. DOI: 10.1073/pnas.0909734107. View

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C . A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol. 2001; 21(5):1874-87. PMC: 86759. DOI: 10.1128/MCB.21.5.1874-1887.2001. View

Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W . Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell. 2008; 3(5):475-9. DOI: 10.1016/j.stem.2008.10.002. View

Xiao G, Lundine D, Annor G, Canar J, Ellison V, Polotskaia A . Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2019; 80(3):394-405. PMC: 7002183. DOI: 10.1158/0008-5472.CAN-19-1036. View

10.

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

11.

Ocana O, Corcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S . Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell. 2012; 22(6):709-24. DOI: 10.1016/j.ccr.2012.10.012. View

12.

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

13.

Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S . Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145. Int J Oncol. 2013; 42(4):1473-81. DOI: 10.3892/ijo.2013.1825. View

14.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

15.

Liu K, Lee J, Kim J, Wang L, Tian Y, Chan S . Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells. Mol Cell. 2017; 68(2):281-292.e5. PMC: 5687282. DOI: 10.1016/j.molcel.2017.09.022. View

16.

Liu C, Srihari S, Le Cao K, Chenevix-Trench G, Simpson P, Ragan M . A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res. 2014; 42(10):6106-27. PMC: 4041457. DOI: 10.1093/nar/gku284. View

17.

Marion R, Strati K, Li H, Murga M, Blanco R, Ortega S . A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009; 460(7259):1149-53. PMC: 3624089. DOI: 10.1038/nature08287. View

18.

Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A . Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988; 8(2):531-9. PMC: 363177. DOI: 10.1128/mcb.8.2.531-539.1988. View

19.

Gandolfi S, Laubach J, Hideshima T, Chauhan D, Anderson K, Richardson P . The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017; 36(4):561-584. DOI: 10.1007/s10555-017-9707-8. View

20.

Junttila M, Karnezis A, Garcia D, Madriles F, Kortlever R, Rostker F . Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature. 2010; 468(7323):567-71. PMC: 3011233. DOI: 10.1038/nature09526. View